Curated News
By: NewsRamp Editorial Staff
January 05, 2026
Alcanza Acquires Tampa Bay Medical Research in Major Clinical Trial Expansion
TLDR
- Alcanza Clinical Research gains a competitive edge by acquiring TBMR's established network and expertise, expanding its national footprint and enhancing clinical trial capabilities.
- Alcanza acquires TBMR, integrating its 40-year legacy, 600+ trials, and 5000 sq ft facilities to create a scalable clinical research network with enhanced operational excellence.
- This acquisition broadens access to innovative treatments for patients, especially underrepresented communities, by combining local expertise with national resources to improve healthcare outcomes.
- Alcanza's acquisition of TBMR merges four decades of medical research with modern infrastructure, accelerating clinical trials for life-changing therapies across diverse regions.
Impact - Why it Matters
This acquisition matters because it represents a significant consolidation in the clinical research industry that directly impacts patient access to cutting-edge medical treatments. As pharmaceutical companies increasingly rely on clinical trial networks to test new therapies, mergers like this one create larger, more efficient organizations that can accelerate research timelines and bring treatments to market faster. For patients in the Tampa Bay region and beyond, this means greater access to potentially life-saving clinical trials, particularly for those from underrepresented communities who have historically faced barriers to participation. The integration of TBMR's nearly four decades of local expertise with Alcanza's national infrastructure creates a powerful combination that could improve clinical trial diversity and outcomes while maintaining the personalized care that patients value. In an era where medical innovation depends heavily on robust clinical research, this strategic move strengthens the pipeline for new treatments across numerous therapeutic areas.
Summary
Alcanza Clinical Research has announced a significant acquisition of Tampa Bay Medical Research (TBMR), a respected independent clinical research center with a nearly four-decade legacy. Founded in 1984, TBMR has completed over 600 clinical trials across broad therapeutic areas for more than 70 pharmaceutical and medical device sponsors, operating from facilities totaling over 5000 sq ft in Clearwater and Largo. This acquisition represents a major strategic move for Alcanza, which operates an integrated network of research facilities focused on bringing clinical trial opportunities to all patients, especially those from under-represented communities. The network includes 25 dedicated research units and additional integrated specialty clinic sites strategically located throughout multiple U.S. regions and Puerto Rico.
The key players in this transaction include Dr. Sureka Bollepalli, CEO and Medical Director of TBMR, a board-certified endocrinologist with over 20 years of experience conducting NIH and industry-sponsored trials, and Carlos Orantes, CEO at Alcanza Clinical Research. Dr. Bollepalli expressed excitement about beginning this next chapter with Alcanza, noting that the partnership strengthens their ability to support patients, deepen community engagement, and expand access to high-quality clinical research. Orantes emphasized that partnering with high-quality clinical research businesses and operators remains a top priority for Alcanza, welcoming Dr. Bollepalli and her TBMR team to the Alcanza family.
This acquisition represents a significant milestone in Alcanza's mission to expand its national footprint while preserving the local expertise and personalized care that TBMR participants and sponsors have come to rely on. By integrating TBMR's operational excellence and community presence with Alcanza's scalable infrastructure and strategic partnerships, the combined organization is poised to accelerate clinical research and broaden access to innovative treatment opportunities for patients. The transaction enhances Alcanza's ability to support studies across all trial phases and major therapeutic areas, bringing cutting-edge therapies closer to patients throughout the Tampa Bay region and beyond. For more information about Alcanza's clinical research network, visit their website at https://alcanzaclinical.com.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, Alcanza Acquires Tampa Bay Medical Research in Major Clinical Trial Expansion
